Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Median Technologies S.A. (ALMDT.PA)
EUR4.35
-0.14 (-3.01%)
FR PAR Healthcare Medical - Devices
Address
1800, Route des CrEtes 6560
Valbonne, FR
Valbonne, FR
CEO
Fredrik Brag
Website
mediantechnologies.com
IPO
2011-05-20
ISIN FR0011049824
Description
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR4.35
-0.14 (-3.01%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
333.4K
Beta
0.54
Float Shares
25.07M
Free Float %
66.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.84% | -2.21% | +9.92% | +9.47% | +61.21% | +12.24% | +141.82% | +8.68% | -63.96% | -35.90% | -47.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.35
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.38
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+1.8% Q4'25: +5.9% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+32.1% ★ Q4'25: -9.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-63.9% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-58.5% Q4'25: -79.7% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%—
-
Share dilution Medical - Devices: 0.0%+98.6% Q4'25: +75.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.59× Q4'25: -0.57× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
886.1K
est: 1.52M (-41.8%)
|
1.20M
est: 1.22M (-1.3%)
|
3.89M
est: 12.10M (-67.9%)
|
6.35M
est: 25.30M (-74.9%)
|
7.69M
est: 41.10M (-81.3%)
|
6.34M
est: 6.30M (+0.6%)
|
8.95M
est: 9.00M (-0.5%)
|
13.48M
est: 13.50M (-0.2%)
|
20.55M
est: 20.50M (+0.2%)
|
23.67M
est: 23.80M (-0.5%)
|
22.23M
est: 22.32M (-0.4%)
|
22.95M
est: 22.90M (+0.2%)
|
23.36M
est: 23.37M (0.0%)
|
26.53M
23.80M – 29.30M
+13.6% YoY
|
35.47M
30.90M – 38.90M
+33.7% YoY
|
50.47M
44.53M – 55.52M
+42.3% YoY
|
105.04M
92.67M – 115.54M
+108.1% YoY
|
| EBITDA |
-4.55M
est: -1.26M (-261.6%)
|
-4.61M
est: -3.86M (-19.3%)
|
-5.43M
est: -10.00M (+45.7%)
|
-8.78M
est: -20.90M (+58.0%)
|
-16.80M
est: -33.96M (+50.5%)
|
-14.52M
est: -5.20M (-179.0%)
|
-7.35M
est: -7.44M (+1.2%)
|
-11.31M
est: -42.83M (+73.6%)
|
-17.10M
est: -67.46M (+74.6%)
|
-17.48M
est: -94.82M (+81.6%)
|
-19.59M
est: -9.15M (-113.9%)
|
-19.28M
est: -110.73M (+82.6%)
|
-13.66M
est: -9.58M (-42.5%)
|
-10.88M
-12.02M – -9.76M
-13.6% YoY
|
-14.55M
-15.95M – -12.67M
-33.7% YoY
|
-20.70M
-22.77M – -18.26M
-42.3% YoY
|
-43.08M
-47.39M – -38.01M
-108.1% YoY
|
| EBIT |
-4.97M
est: -1.34M (-272.3%)
|
-2.21M
est: -3.83M (+42.3%)
|
-5.51M
est: -10.61M (+48.1%)
|
-9.18M
est: -22.19M (+58.6%)
|
-17.12M
est: -36.05M (+52.5%)
|
-15.31M
est: -5.53M (-177.1%)
|
-7.97M
est: -7.89M (-1.0%)
|
-12.02M
est: -42.47M (+71.7%)
|
-17.67M
est: -66.90M (+73.6%)
|
-18.23M
est: -94.03M (+80.6%)
|
-20.81M
est: -9.13M (-127.8%)
|
-21.30M
est: -109.84M (+80.6%)
|
-13.66M
est: -9.56M (-42.9%)
|
-10.86M
-11.99M – -9.74M
-13.6% YoY
|
-14.51M
-15.91M – -12.64M
-33.7% YoY
|
-20.65M
-22.71M – -18.22M
-42.3% YoY
|
-42.97M
-47.27M – -37.91M
-108.1% YoY
|
| Net Income |
-3.98M
est: -14.48M (+72.5%)
|
-4.35M
est: -3.18M (-36.5%)
|
-5.53M
est: -2.96M (-86.8%)
|
-9.11M
est: 15.90M (-157.3%)
|
-17.21M
est: 37.54M (-145.8%)
|
-15.28M
|
-7.99M
est: -14.61M (+45.3%)
|
-12.80M
est: -35.29M (+63.7%)
|
-19.29M
est: -55.59M (+65.3%)
|
-20.21M
est: -21.42M (+5.6%)
|
-22.98M
est: -46.81M (+50.9%)
|
-25.24M
est: -43.75M (+42.3%)
|
-34.07M
est: -17.55M (-94.1%)
|
-15.23M
-28.64M – -9.55M
+13.2% YoY
|
-11.23M
-29.38M – -6.98M
+26.3% YoY
|
-14.61M
-16.70M – -12.51M
-30.0% YoY
|
-32.58M
-36.82M – -27.59M
-123.1% YoY
|
| SGA |
1.54M
est: 296.9K (+419.7%)
|
1.56M
est: 237.5K (+558.9%)
|
3.13M
est: 2.36M (+32.6%)
|
5.04M
est: 4.93M (+2.1%)
|
7.33M
est: 8.01M (-8.6%)
|
7.52M
est: 1.23M (+512.3%)
|
5.95M
est: 1.76M (+239.1%)
|
281.0K
est: 2.63M (-89.3%)
|
421.0K
est: 4.00M (-89.5%)
|
759.0K
est: 4.64M (-83.6%)
|
739.0K
est: 4.26M (-82.7%)
|
19.93M
est: 4.37M (+356.0%)
|
—
est: 4.46M (-100.0%)
|
5.06M
4.54M – 5.59M
+13.6% YoY
|
6.77M
5.90M – 7.42M
+33.7% YoY
|
9.63M
8.50M – 10.60M
+42.3% YoY
|
20.05M
17.69M – 22.05M
+108.1% YoY
|
| EPS |
-0.67
est: -0.78 (+14.4%)
|
-0.72
est: -0.79 (+9.2%)
|
-0.43
est: -0.16 (-168.8%)
|
-0.66
est: 0.86 (-176.7%)
|
-1.26
est: 2.03 (-162.1%)
|
-1.15
|
-0.66
est: -0.79 (+16.5%)
|
-1.06
est: -0.75 (-42.3%)
|
-1.25
est: -0.90 (-38.9%)
|
-1.28
est: -1.20 (-7.0%)
|
-1.25
est: -1.29 (+3.1%)
|
-1.37
est: -1.21 (-13.7%)
|
-0.93
est: -0.54 (-72.9%)
|
-0.49
-0.78 – -0.26
+9.5% YoY
|
-0.41
-0.80 – -0.19
+16.4% YoY
|
-0.40
-0.45 – -0.34
+1.0% YoY
|
-0.89
-1.00 – -0.75
-120.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.76M
OE per share TTM
-1.38
Owner's Yield
-13.70%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-60.7K
Shares Outstanding
37.62M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fredrik Brag | Founder, GM, Chief Executive Officer & Director | 698.0K | male |
| Chrystel Brun | Chief Human Resources Officer | — | female |
| Emmanuelle Leygues | Vice President of Corporate Marketing & Financial Communications | — | female |
| Jean-Christophe Montigny | Chief Financial Officer | — | male |
| Nicolas Dano | Chief Operating Officer & Chief Commercial Officer of iCRO | — | male |
| Thomas Bonnefont | Chief Operating Officer & Chief Commercial Officer eyonis Business Unit | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALMDT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
